scholarly journals Optimal duration for fetal monitoring for patients admitted with PPROM

2022 ◽  
Vol 226 (1) ◽  
pp. S548-S549
Author(s):  
Vivek Katukuri ◽  
Whitney Elks ◽  
Danielle Esters ◽  
Trevor Quiner ◽  
Conrad Chao
Keyword(s):  
Fetal Monitoring ◽  
Optimal Duration

FDA Advisory Panel OKs Fetal Monitoring Device

Ob Gyn News ◽  
2005 ◽  
Vol 40 (14) ◽  
pp. 1-2
Author(s):  
CHRISTINE KILGORE
Keyword(s):  
Fetal Monitoring ◽  
Advisory Panel ◽  
Monitoring Device

Idiopathic venous thrombosis

2006 ◽  
Vol 26 (01) ◽  
pp. 52-54 ◽  
Author(s):  
P. A. Kyrle
Keyword(s):  
Chronic Disease ◽  
Venous Thrombosis ◽  
Vitamin K ◽  
Clinical Benefit ◽  
Plasma Levels ◽  
Vitamin K Antagonists ◽  
Antithrombin Deficiency ◽  
Optimal Duration ◽  
Risk Of Treatment

SummaryVenous thrombosis is a chronic disease with a recurrence rate of approximately 30% within 5-8 years. The optimal duration of secondary thromboprophylaxis in these patients entails balancing the risk of recurrence against the risk of treatment-associated bleeding. There is agreement that patients with a first idiopathic venous thrombosis should receive vitamin K antagonists for at least 3-6 months. Convincing trials showing a clinical benefit in terms of morbidity or mortality with respect to expansion of anticoagulation beyond 6 months are lacking. Nevertheless, some subgroups of patients with venous thrombosis may benefit from indefinite anticoagulation. Thus, patients with antithrombin deficiency, combined or homozygous defects, more than one unprovoked episode of thrombosis, the lupus anticoagulant or high factor VIII plasma levels are good candidates for long-term prevention.

Fetal Monitoring und Pulsoximetrie-Vergleich der Systeme

2006 ◽  
Vol 66 (S 01) ◽  
Author(s):  
A Nonnenmacher ◽  
N Fuhr ◽  
H Hopp ◽  
J Dudenhausen
Keyword(s):  
Fetal Monitoring

Improved fetal monitoring through individualized growth charts for ultrasound measurements

2007 ◽  
Vol 211 (S 2) ◽  
Author(s):  
C Hörmansdörfer ◽  
A Scharf ◽  
I Staboulidou ◽  
P Hillemanns ◽  
P Schmidt
Keyword(s):  
Fetal Monitoring ◽  
Growth Charts ◽  
Ultrasound Measurements

Optimal duration of dual antiplatelet therapy following PTA of the superficial femoral artery: the DAPT-SFA protocol

2020 ◽  
Vol 61 (3) ◽  
Author(s):  
Enrico M. Marone ◽  
Luigi F. Rinaldi ◽  
Simona Chierico ◽  
Giulia Marazzi ◽  
Piernicola Palmieri ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Femoral Artery ◽  
Superficial Femoral Artery ◽  
Dual Antiplatelet Therapy ◽  
Optimal Duration

Optimal Duration of the Preincubation Phase in Enzyme Inhibition Experiments

2020 ◽  
Author(s):  
Petr Kuzmic
Keyword(s):  
Enzyme Inhibition ◽  
Dose Response ◽  
Enzyme Inhibitor ◽  
Single Point ◽  
Association Rate ◽  
Weakly Bound ◽  
Inhibitor Complex ◽  
Dissociation Equilibrium ◽  
Optimal Duration ◽  
Algebraic Formula

This report describes an algebraic formula to calculate the optimal duration of the pre-incubation phase in enzyme-inhibition experiments, based on the assumed range of expected values for the dissociation equilibrium constant of the enzyme–inhibitor complex and for the bimolecular association rate constant. Three typical experimental scenarios are treated, namely, (1) single-point primary screening at relatively high inhibitor concentrations; (2) dose-response secondary screening of relatively weakly bound inhibitors; (3) dose-response screening of tightly-bound inhibitors.

738 Sex-specific differences in electronic fetal monitoring patterns

2021 ◽  
Vol 224 (2) ◽  
pp. S462-S463
Author(s):  
Erin Bailey ◽  
Nandini Raghuraman ◽  
Fan Zhang ◽  
Jeny Ghartey ◽  
George A. Macones ◽  
...  
Keyword(s):  
Fetal Monitoring ◽  
Electronic Fetal Monitoring
Sign in / Sign up

Export Citation Format

Share Document